www.fgks.org   »   [go: up one dir, main page]

WO2022038955A1 - Virus inactivating agent composition, virus inactivation efficacy enhancing method, and virus inactivation method - Google Patents

Virus inactivating agent composition, virus inactivation efficacy enhancing method, and virus inactivation method Download PDF

Info

Publication number
WO2022038955A1
WO2022038955A1 PCT/JP2021/027348 JP2021027348W WO2022038955A1 WO 2022038955 A1 WO2022038955 A1 WO 2022038955A1 JP 2021027348 W JP2021027348 W JP 2021027348W WO 2022038955 A1 WO2022038955 A1 WO 2022038955A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
mass
virus inactivating
agent composition
component
Prior art date
Application number
PCT/JP2021/027348
Other languages
French (fr)
Japanese (ja)
Inventor
裕之 小野寺
由美子 市村
幸治 中山
Original Assignee
大日本除蟲菊株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大日本除蟲菊株式会社 filed Critical 大日本除蟲菊株式会社
Priority to CN202180058669.4A priority Critical patent/CN116056570A/en
Priority to JP2022543335A priority patent/JPWO2022038955A1/ja
Publication of WO2022038955A1 publication Critical patent/WO2022038955A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/12—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
    • A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
    • A01N47/44—Guanidine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Patent Document 5 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butane dibromide and found that this compound is also specifically effective against norovirus.
  • Patent Document 5 the norovirus inactivating agent of Patent Document 5 is excellent, there is still room for study to improve its performance in terms of its rapid effect on virus inactivation.
  • the cationic virus inactivating component is a dialkyldimethylammonium salt (however, the alkyl group is the same or different, and the direct number of carbon atoms is 8 to 20. (Representing a chain saturated hydrocarbon), trialkyl (3-triethoxysilylpropyl) ammonium salt (provided that the alkyl groups are the same or different and represent a linear saturated hydrocarbon having 1 to 18 carbon atoms), 1.
  • the present invention is characterized in that (c) ethanol is blended in an amount of 10% by mass to 80% by mass in the virus inactivating agent composition having the above constitution.
  • the present invention is characterized in that, in the virus inactivating agent composition having the above constitution, the blending amount of (c) ethanol is 35% by mass to 65% by mass.
  • the compounding mass ratio (a) / (b) of the (b) virus inactivating efficacy enhancing component to the (a) virus inactivating component is determined. , 0.001 ⁇ (a) / (b) ⁇ 250.
  • the present invention comprises (a) a virus inactivating agent composition containing 0.01% by mass to 5.0% by mass of a cationic virus inactivating component and water as a virus inactivating component.
  • a virus inactivating efficacy enhancing component one or more selected from the group consisting of 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid. It is a method for enhancing virus inactivating efficacy, which is characterized by addition.
  • the present invention is also a method for inactivating a non-enveloped virus in which the virus inactivating agent composition having the above constitution is brought into contact with the non-enveloped virus.
  • a cationic virus inactivating component of 0.01% by mass to 5.0% by mass as a virus inactivating component, and (b) a virus inactivating effect.
  • a virus inactivating agent composition is excellent in usability without fear of irritation due to alkali to the skin and has excellent rapid effect in virus inactivation.
  • the cationic virus inactivating component is a dialkyldimethylammonium salt (however, the alkyl group is the same or the same or Unlike each other, it represents a linear saturated hydrocarbon having 8 to 20 carbon atoms) and a trialkyl (3-triethoxysilylpropyl) ammonium salt (provided that the alkyl groups are the same or different from each other and have 1 to 18 carbon atoms.
  • virus inactivating agent composition capable of more effectively improving the rapid effect in virus inactivation can be obtained.
  • the cationic virus inactivating component is 1,4-bis (3,3'-(1). -Decilpyridinium) Methyloxy) Butane dibromide, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, chlorhexidine gluconate, and octadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride.
  • a virus inactivating agent composition capable of more effectively improving the rapid effect in virus inactivation can be obtained.
  • the amount of (c) ethanol blended is 35% by mass to 65% by mass, so that the virus A virus with excellent quick-drying properties can be more effectively improved in inactivation, less likely to cause skin irritation during use, and effectively improve the volatilization of the virus inactivating agent composition. It becomes an inactivating agent composition.
  • the virus inactivating agent composition having the configuration of any one of the first to fifth above, (a) the virus is inactive against the virus inactivating component (b).
  • the compounding mass ratio (a) / (b) of the compounding efficacy enhancing component is 0.001 ⁇ (a) / (b) ⁇ 250, the rapid effect in virus inactivation can be further improved.
  • the virus inactivating component contains 0.01% by mass to 5.0% by mass of a cationic virus inactivating component and water.
  • the virus inactivating agent composition is selected from the group consisting of (b) 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid as a virus inactivating efficacy enhancing component.
  • the (a) cationic virus inactivating component compounded as a virus inactivating component in the virus inactivating agent composition of the present invention has a high virus inactivating effect, but is virus inactivating. There was room for consideration in the rapid effect on activation.
  • a cationic virus inactivating component in combination with one or more selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid, in virus inactivation. It is the first finding by the present inventors that the rapid effect could be improved synergistically.
  • an organic acid and / or an inorganic acid which is a virus inactivating efficacy enhancing component is a virus inactivating agent. It is blended in an amount of 0.02% by mass or more and 10.0% by mass or less with respect to the composition, preferably 0.03% by mass or more and 5.0% by mass or less, and 0.10% by mass or more and 2.0% by mass or less. The following is more preferable.
  • any of anionic surfactant, nonionic surfactant and amphoteric surfactant is preferably used.
  • the blending amount of the surfactant in the virus inactivating agent composition of the present invention is not particularly limited, but is preferably 0.1% by mass or more and 10% by mass or less.
  • the cationic virus inactivating component contained in the virus inactivating agent composition of the present invention is not included in the surfactant in the present specification.
  • anionic surfactants include fatty acid soaps, alkylbenzene sulfonates, linear alkylbenzene sulfonates, alkyl sulfates, ⁇ -olefin sulfonates, alkyl phosphate ester salts, polyoxyethylene alkyl ether sulfates, etc. Examples thereof include polyoxyethylene alkyl phenyl ether sulfate and polyoxyethylene alkyl ether phosphate.
  • nonionic surfactants include polyoxyethylene alkyl ethers, polyoxyethylene alkyl phenyl ethers, polyoxyethylene higher fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene glycerin fatty acid esters, and polyoxyethylene hydrogenated castor oil. , Palm oil fatty acid diethanolamide, polyoxyethylene polyoxypropylene alkyl ether, fatty acid alkanolamide, alkylamine oxide and the like.
  • amphoteric surfactants include betaine-type surfactants. Specific examples thereof include lauryl-N, N-dimethylacetate betaine, laurylamide propyl-N, N-dimethylacetate betaine, coconut alkylamide propyl-N, N-dimethylhydroxypropyl sulfobetaine and the like.
  • the virus inactivating agent composition of the present invention is an aqueous type, and water is mainly used as the solvent.
  • water examples include purified water such as ion-exchanged water and reverse osmosis membrane water, ordinary tap water, industrial water, and deep ocean water.
  • virus inactivating agent composition of the present invention as other components, as necessary, antibacterial agents other than cationic virus inactivating components, virus inactivating agents, algae-proofing agents, rust-preventing agents, etc.
  • a solvent, a chelating agent, a fragrance, a deodorant component, a pH adjuster, a moisturizing component, a thickener, etc. within a range that does not impair the effects of the present invention, an antibacterial effect, a virus inactivating effect, an algae-proofing effect, etc.
  • Anti-corrosion effect, cleaning effect, fragrance, deodorant property, moisturizing effect, thickening effect and the like may be imparted.
  • the solvent examples include normal paraffin, isoparaffin, liquid paraffin, naphthenic hydrocarbon, vaseline, squalane, hydrocarbon solvent such as ⁇ -olefin oligomer, 1-propanol, 2-propanol (IPA), 1-butanol, 2 -Alcohol solvents such as butanol, tertiary butanol, 1-pentanol, 1-hexanol, benzyl alcohol, 2-phenylethanol, 2-phenoxyethanol (ethylene glycol monophenyl ether), ethylene glycol, propylene glycol, 1-phenoxy-
  • glycol-based solvents such as 2-propanol (propylene glycol phenyl ether), 1,3-butylene glycol, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, and tripropylene glycol monobutyl ether.
  • fragrances include limonene such as d-lymonen, pinen such as ⁇ -pinen and ⁇ -pinen, simen such as p-simene, hydrocarbon fragrances such as inden and cariophyllene, linalol, geraniol, citronellol, and l-menthol.
  • Vanillin, Ethylvanylin and other phenolic fragrances octanal, nonanal, undecylaldehyde, undecanal, decylaldehyde, n-butylaldehyde, isobutylaldehyde, hexylaldehyde, citral, terpineol, benzaldehyde, cinnamic aldehyde, anisaldehyde, cumin Aldehyde-based fragrances such as aldehydes, adxal, amilcinnamic aldehydes, and cyclamen aldehydes, muskketones, carboxylics, mentons, cerebral brains, camphor, acetophenone, butyrophenone, tonalide, ⁇ -ionone, ⁇ -ionone, ⁇ -methylionone, ⁇ -methylionone, ⁇ -Ketone-
  • deodorant components include sugar cane extract, green tea extract, cha dry distillate, persimmon extract, grapefruit extract, mozochiku extract, yuzu seed extract, and lotus extract, but in addition to the deodorizing effect. Therefore, sugar cane extract is suitable from the viewpoint of promoting the inactivating action of norovirus.
  • pH adjuster examples include other organic acids such as acetic acid, malic acid and salicylic acid, other inorganic acids such as hydrochloric acid, sodium citrate, sodium carbonate, sodium hydrogencarbonate, sodium hydroxide and the like.
  • moisturizing ingredients include glycols such as glycerin, propylene glycol and 1,3-butylene glycol, and polyhydric alcohols such as sorbitol.
  • thickeners examples include carboxyvinyl polymers, which are cross-linked polyacrylic acids, cellulose derivatives such as carboxymethyl cellulose, hydroxyethyl cellulose, and hydroxypupyl cellulose, xanthan gum, guar gum, arabic gum, sodium alginate, propylene glycol alginate, and ethyl cellulose. , Sodium polyacrylate, cyclodextrin and the like.
  • the virus inactivating agent composition of the present invention thus obtained is applied or sprayed to a place touched by a virus-infected person, a place where a virus-infected person's vomit is treated, or a place contaminated with a virus such as clothes. Therefore, the virus can be effectively removed.
  • the virus adhering to the fingers or the like can be effectively removed and the fingers or the like can be disinfected.
  • the virus inactivating composition of the present invention is highly resistant to enveloped viruses such as influenza virus, coronavirus and herpesvirus, as well as non-enveloped viruses such as norovirus, rotavirus, rhinovirus and adenovirus. Has an activating effect. Therefore, it can also be suitably used for inactivating norovirus, which was difficult to inactivate with conventional virus removing agents.
  • test virus solution 0.1 mL was added and mixed with 0.9 mL of the test solutions of the present inventions 1 to 10 and Comparative Examples 1 to 6 prepared in Example 1 to prepare an action solution. After 1 minute, the working solution was diluted 100-fold with MEM medium to prepare a 10-fold dilution series. The same operation was performed using a phosphate buffered saline solution to which the test virus solution was added as a control.
  • Comparative Examples 5 and 6 containing only the component (a) and Comparative Examples 1 to 3 containing only the component (b) were against feline calicivirus. Therefore, the reduction value of the infectious titer log was smaller than 1.5, and a sufficient virus inactivating effect was not observed. Further, in Comparative Example 4 in which the component (a) was replaced with the cationic virus inactivating component and isopropylmethylphenol, which is another virus inactivating component, was used, the component (b) was used in combination for immediate effect. No virus inactivating effect was obtained, and no enhancing effect was observed in the component (b).
  • the infectious titer logarithmic reduction value was 3.0. It was confirmed that a faster-acting virus inactivating effect could be obtained.
  • test virus solution 0.1 mL was added and mixed with 0.9 mL of the test solution of the present invention 12 prepared in Example 1 to prepare an action solution. After 3 minutes, the working solution was diluted 100-fold with MEM medium to stop the action, and the virus infectious titer was measured as the stock solution of the sample for infectious titer measurement. The same operation was performed using a phosphate buffered saline solution to which the test virus solution was added as a control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dentistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

Provided is a virus inactivating agent composition characterized by blending (a) 0.01 mass% to 5.0 mass% of a cationic virus inactivating component as a virus inactivating component, (b) 0.02 mass% to 10.0 mass% of one, two, or more components selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid, as virus inactivation efficacy enhancing components, and water.

Description

ウイルス不活性化剤組成物およびウイルス不活性化効力増強方法、並びにウイルス不活性化方法A virus inactivating agent composition, a method for enhancing the efficacy of virus inactivation, and a method for inactivating virus.
　本発明は、ウイルス不活性化における速効性が優れるウイルス不活性化剤組成物およびウイルス不活性化効力増強方法、並びにウイルス不活性化方法に関する。 The present invention relates to a virus inactivating agent composition having an excellent rapid effect on virus inactivation, a method for enhancing the efficacy of virus inactivation, and a method for inactivating virus.
　大腸菌Ｏ－１５７による食中毒事件の多発に始まり、その後、新型肺炎ＳＡＲＳが猛威を振い、ここ数年はノロウイルスによる食中毒が多発している。２００９年の春には新型インフルエンザが発生してパンデミック寸前の状態になり、除菌衛生に対する関心は高まる一方である。大腸菌Ｏ－１５７による食中毒事件が多発した１９９６年以降、多くの家庭用品で抗菌性が付与されており、使用される薬剤としては、銀、銅などの金属化合物を利用したものが多い。例えば、銀ブロム又はヨード錯体の塩を含有する抗菌性繊維（特許文献１）が知られているが、その防カビ効果は小さく、ウイルスに対する効果も十分でない。 Beginning with frequent outbreaks of food poisoning due to Escherichia coli O-157, the new type of pneumonia SARS has been rampant, and food poisoning due to norovirus has been frequent in recent years. In the spring of 2009, a new influenza outbreak occurred and the situation was on the verge of a pandemic, and interest in sterilization hygiene is increasing. Since 1996, when food poisoning cases caused by Escherichia coli O-157 occurred frequently, antibacterial properties have been imparted to many household products, and many of the drugs used are those using metal compounds such as silver and copper. For example, an antibacterial fiber containing a salt of silver brom or an iodine complex (Patent Document 1) is known, but its antifungal effect is small and its effect on viruses is not sufficient.
　一方、抗ウイルス剤もしくは抗ウイルス効果を謳った製品も、いくつか提案されている。例えば、少なくとも一箇所にフェノール性水酸基を有する、非水溶性の芳香族ヒドロキシ化合物を有効成分とする抗ウイルス剤を塗布あるいは混合させてなる繊維（特許文献２）、ポリオキシエチレン（ジメチルイミノ）エチレン（ジメチルイミノ）エチレンジクロライドを含有する繊維用抗ウイルス加工剤（特許文献３）、２－ピリジンチオール亜鉛－１－オキシド、２－ピリジンチオール銅－１－オキシド、又はこれらの両方を含む抗ウイルス剤で処理された抗ウイルス性繊維（特許文献４）等が知られている。 On the other hand, some products claiming antiviral agents or antiviral effects have also been proposed. For example, a fiber (Patent Document 2) formed by applying or mixing an antiviral agent containing a water-insoluble aromatic hydroxy compound having a phenolic hydroxyl group at at least one position as an active ingredient (Patent Document 2), polyoxyethylene (dimethylimino) ethylene. (Dimethylimino) Antiviral processing agent for fibers containing ethylene dichloride (Patent Document 3), 2-pyridinethiol zinc-1-oxide, 2-pyridinthiol copper-1-oxide, or an antiviral agent containing both of them. Antiviral fibers treated with (Patent Document 4) and the like are known.
　さらに本出願人は、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイドに着目し、この化合物がノロウイルスに対しても特異的に有効であることを見出した（特許文献５）。特許文献５のノロウイルス不活性化剤は優れたものであるが、ウイルス不活性化における速効性においては、性能を向上するための検討をする余地が残されていた。 Furthermore, the applicant focused on 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butane dibromide and found that this compound is also specifically effective against norovirus. (Patent Document 5). Although the norovirus inactivating agent of Patent Document 5 is excellent, there is still room for study to improve its performance in terms of its rapid effect on virus inactivation.
　特に近年、新型コロナウイルス等の感染症の流行に伴い、日常的に消毒をする機会が増えている。そのため、ウイルス不活性化における速効性を向上させることは使用者が消毒に費やす時間の短縮にもつながるため、重要な課題である。 Especially in recent years, with the epidemic of infectious diseases such as the new coronavirus, opportunities for daily disinfection are increasing. Therefore, improving the rapid effect on virus inactivation is an important issue because it also leads to a reduction in the time spent by the user for disinfection.
特開２００８－３３８４８１号公報Japanese Unexamined Patent Publication No. 2008-338481 特開２００５－１１２７４８号公報Japanese Unexamined Patent Publication No. 2005-112748 特開２００８－１１５５０６号公報Japanese Unexamined Patent Publication No. 2008-115506 特開２００９－７７３６号公報Japanese Unexamined Patent Publication No. 2009-7736 特許第５３７７０９８号Patent No. 5377098
　本発明は、ウイルス不活性化における速効性が優れるウイルス不活性化剤組成物およびウイルス不活性化効力増強方法、並びにウイルス不活性化方法を提供することを目的とする。 An object of the present invention is to provide a virus inactivating agent composition having an excellent rapid effect on virus inactivation, a method for enhancing the virus inactivating efficacy, and a method for inactivating a virus.
　上記目的を達成するために本発明は、（ａ）ウイルス不活性化成分として、０．０１質量％～５．０質量％のカチオン系ウイルス不活性化成分と、（ｂ）ウイルス不活性化効力増強成分として、０．０２質量％～１０．０質量％のフマル酸、リン酸、乳酸、及びクエン酸からなる群より選択される１種又は２種以上と、水と、を配合したことを特徴とするウイルス不活性化剤組成物である。 In order to achieve the above object, the present invention comprises (a) 0.01% by mass to 5.0% by mass of a cationic virus inactivating component and (b) virus inactivating efficacy as a virus inactivating component. As the enhancing component, one or more selected from the group consisting of 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid, and water were blended. It is a characteristic virus inactivating agent composition.
　また本発明は、上記構成のウイルス不活性化剤組成物において、前記カチオン系ウイルス不活性化成分が、ジアルキルジメチルアンモニウム塩（但し、前記アルキル基は同一又は相異なり、炭素数８～２０の直鎖飽和炭化水素を表す。）、トリアルキル（３－トリエトキシシリルプロピル）アンモニウム塩（但し、前記アルキル基は同一又は相異なり、炭素数１～１８の直鎖飽和炭化水素を表す。）、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタン塩、ベンザルコニウム塩、ベンゼトニウム塩、クロルヘキシジン塩からなる群より選択される１種又は２種以上であることを特徴としている。 Further, in the present invention, in the virus inactivating agent composition having the above constitution, the cationic virus inactivating component is a dialkyldimethylammonium salt (however, the alkyl group is the same or different, and the direct number of carbon atoms is 8 to 20. (Representing a chain saturated hydrocarbon), trialkyl (3-triethoxysilylpropyl) ammonium salt (provided that the alkyl groups are the same or different and represent a linear saturated hydrocarbon having 1 to 18 carbon atoms), 1. , 4-Bis (3,3'-(1-decylpyridinium) methyloxy) butane salt, benzalkonium salt, benzethonium salt, chlorhexidine salt, one or more selected from the group. It is supposed to be.
　また本発明は、上記構成のウイルス不活性化剤組成物において、前記カチオン系ウイルス不活性化成分は、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイド、塩化ベンザルコニウム、塩化ベンゼトニウム、塩化ジデシルジメチルアンモニウム、クロルヘキシジングルコン酸塩、及び塩化オクタデシルジメチル（３－トリエトキシシリルプロピル）アンモニウムからなる群より選択される１種又は２種以上であることを特徴としている。 Further, in the present invention, in the virus inactivating agent composition having the above constitution, the cationic virus inactivating component is 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butane dibromide. , One or more selected from the group consisting of benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, chlorhexidine gluconate, and octadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride. It is a feature.
　また本発明は、上記構成のウイルス不活性化剤組成物において、（ｃ）エタノールを１０質量％～８０質量％を配合したことを特徴としている。 Further, the present invention is characterized in that (c) ethanol is blended in an amount of 10% by mass to 80% by mass in the virus inactivating agent composition having the above constitution.
　また本発明は、上記構成のウイルス不活性化剤組成物において、前記（ｃ）エタノールの配合量は、３５質量％～６５質量％であることを特徴としている。 Further, the present invention is characterized in that, in the virus inactivating agent composition having the above constitution, the blending amount of (c) ethanol is 35% by mass to 65% by mass.
　また本発明は、上記構成のウイルス不活性化剤組成物において、前記（ａ）ウイルス不活性化成分に対する前記（ｂ）ウイルス不活性化効力増強成分の配合質量比（ａ）／（ｂ）が、０．００１≦（ａ）／（ｂ）≦２５０であることを特徴としている。 Further, in the present invention, in the virus inactivating agent composition having the above constitution, the compounding mass ratio (a) / (b) of the (b) virus inactivating efficacy enhancing component to the (a) virus inactivating component is determined. , 0.001 ≦ (a) / (b) ≦ 250.
　また本発明は、（ａ）ウイルス不活性化成分として、０．０１質量％～５．０質量％のカチオン系ウイルス不活性化成分と、水と、を含有するウイルス不活性化剤組成物に、（ｂ）ウイルス不活性化効力増強成分として、０．０２質量％～１０．０質量％のフマル酸、リン酸、乳酸、及びクエン酸からなる群より選択される１種又は２種以上を添加することを特徴とするウイルス不活性化効力増強方法である。 Further, the present invention comprises (a) a virus inactivating agent composition containing 0.01% by mass to 5.0% by mass of a cationic virus inactivating component and water as a virus inactivating component. , (B) As a virus inactivating efficacy enhancing component, one or more selected from the group consisting of 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid. It is a method for enhancing virus inactivating efficacy, which is characterized by addition.
　また本発明は、上記構成のウイルス不活性化剤組成物をノンエンベロープウイルスに対して接触させるノンエンベロープウイルスの不活性化方法である。 The present invention is also a method for inactivating a non-enveloped virus in which the virus inactivating agent composition having the above constitution is brought into contact with the non-enveloped virus.
　本発明の第１の構成によれば、（ａ）ウイルス不活性化成分として、０．０１質量％～５．０質量％のカチオン系ウイルス不活性化成分と、（ｂ）ウイルス不活性化効力増強成分として、０．０２質量％～１０．０質量％のフマル酸、リン酸、乳酸、及びクエン酸からなる群より選択される１種又は２種以上と、水と、を配合することにより、皮膚に対するアルカリによる刺激のおそれがなく使用感に優れ、且つウイルス不活性化における速効性が優れたウイルス不活性化剤組成物となる。 According to the first configuration of the present invention, (a) a cationic virus inactivating component of 0.01% by mass to 5.0% by mass as a virus inactivating component, and (b) a virus inactivating effect. By blending one or more selected from the group consisting of 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid, and water as the enhancing component. The virus inactivating agent composition is excellent in usability without fear of irritation due to alkali to the skin and has excellent rapid effect in virus inactivation.
　また、本発明の第２の構成によれば、上記第１の構成のウイルス不活性化剤組成物において、カチオン系ウイルス不活性化成分は、ジアルキルジメチルアンモニウム塩（但し、前記アルキル基は同一又は相異なり、炭素数８～２０の直鎖飽和炭化水素を表す。）、トリアルキル（３－トリエトキシシリルプロピル）アンモニウム塩（但し、前記アルキル基は同一又は相異なり、炭素数１～１８の直鎖飽和炭化水素を表す。）、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタン塩、ベンザルコニウム塩、ベンゼトニウム塩、クロルヘキシジン塩からなる群より選択される１種又は２種以上を用いることにより、ウイルス不活性化における速効性をより効果的に向上させることができるウイルス不活性化剤組成物となる。 Further, according to the second configuration of the present invention, in the virus inactivating agent composition of the first configuration, the cationic virus inactivating component is a dialkyldimethylammonium salt (however, the alkyl group is the same or the same or Unlike each other, it represents a linear saturated hydrocarbon having 8 to 20 carbon atoms) and a trialkyl (3-triethoxysilylpropyl) ammonium salt (provided that the alkyl groups are the same or different from each other and have 1 to 18 carbon atoms. (Representing a chain saturated hydrocarbon), 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butane salt, benzalconium salt, benzethonium salt, chlorhexidine salt selected from the group 1 By using a seed or two or more kinds, a virus inactivating agent composition capable of more effectively improving the rapid effect in virus inactivation can be obtained.
　また、本発明の第３の構成によれば、上記第２の構成のウイルス不活性化剤組成物において、カチオン系ウイルス不活性化成分は、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイド、塩化ベンザルコニウム、塩化ベンゼトニウム、塩化ジデシルジメチルアンモニウム、クロルヘキシジングルコン酸塩、及び塩化オクタデシルジメチル（３－トリエトキシシリルプロピル）アンモニウムからなる群より選択される１種又は２種以上を用いることにより、ウイルス不活性化における速効性をより効果的に向上させることができるウイルス不活性化剤組成物となる。 Further, according to the third configuration of the present invention, in the virus inactivating agent composition of the second configuration, the cationic virus inactivating component is 1,4-bis (3,3'-(1). -Decilpyridinium) Methyloxy) Butane dibromide, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, chlorhexidine gluconate, and octadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride. By using one kind or two or more kinds, a virus inactivating agent composition capable of more effectively improving the rapid effect in virus inactivation can be obtained.
　また、本発明の第４の構成によれば、上記第１～第３のいずれか１の構成のウイルス不活性化剤組成物において、（ｃ）エタノールを１０質量％～８０質量％を配合することにより、ウイルス不活性化における速効性を向上させることができ、さらにウイルス不活性化剤組成物の揮散性も向上することから、速乾性に優れるウイルス不活性化剤組成物となる。 Further, according to the fourth configuration of the present invention, (c) ethanol is blended in an amount of 10% by mass to 80% by mass in the virus inactivating agent composition having any one of the first to third configurations. As a result, the rapid effect on virus inactivation can be improved, and the volatility of the virus inactivating agent composition is also improved, so that the virus inactivating agent composition having excellent quick-drying property can be obtained.
　また、本発明の第５の構成によれば、上記第４の構成のウイルス不活性化剤組成物において、（ｃ）エタノールの配合量は、３５質量％～６５質量％であることにより、ウイルス不活性化における速効性をより効果的に向上させることができ、使用時に皮膚刺激が出にくく、さらにウイルス不活性化剤組成物の揮散性も効果的に向上することから、速乾性に優れるウイルス不活性化剤組成物となる。 Further, according to the fifth configuration of the present invention, in the virus inactivating agent composition of the fourth configuration, the amount of (c) ethanol blended is 35% by mass to 65% by mass, so that the virus A virus with excellent quick-drying properties can be more effectively improved in inactivation, less likely to cause skin irritation during use, and effectively improve the volatilization of the virus inactivating agent composition. It becomes an inactivating agent composition.
　また、本発明の第６の構成によれば、上記第１～第５のいずれか１の構成のウイルス不活性化剤組成物において、（ａ）ウイルス不活性化成分に対する（ｂ）ウイルス不活性化効力増強成分の配合質量比（ａ）／（ｂ）が、０．００１≦（ａ）／（ｂ）≦２５０であることにより、ウイルス不活性化における速効性をより向上させることができる。 Further, according to the sixth configuration of the present invention, in the virus inactivating agent composition having the configuration of any one of the first to fifth above, (a) the virus is inactive against the virus inactivating component (b). When the compounding mass ratio (a) / (b) of the compounding efficacy enhancing component is 0.001 ≦ (a) / (b) ≦ 250, the rapid effect in virus inactivation can be further improved.
　また、本発明の第７の構成によれば、（ａ）ウイルス不活性化成分として、０．０１質量％～５．０質量％のカチオン系ウイルス不活性化成分と、水と、を含有するウイルス不活性化剤組成物に、（ｂ）ウイルス不活性化効力増強成分として、０．０２質量％～１０．０質量％のフマル酸、リン酸、乳酸、及びクエン酸からなる群より選択される１種又は２種以上を添加することにより、ウイルス不活性化成分であるカチオン系ウイルス不活性化成分のウイルス不活性化における速効性を向上させることができるウイルス不活性化剤組成物を製造可能となる。 Further, according to the seventh configuration of the present invention, (a) the virus inactivating component contains 0.01% by mass to 5.0% by mass of a cationic virus inactivating component and water. The virus inactivating agent composition is selected from the group consisting of (b) 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid as a virus inactivating efficacy enhancing component. A virus inactivating agent composition capable of improving the rapid effect of a cationic virus inactivating component, which is a virus inactivating component, in virus inactivation by adding one or more of them. It will be possible.
　また、本発明の第８の構成によれば、上記第１～第６のいずれか１の構成のウイルス不活性化剤組成物をノンエンベロープウイルスに対して接触させることにより、薬剤感受性が低く、不活性化が困難なノンエンベロープウイルスの効果的な不活性化方法となる。 Further, according to the eighth configuration of the present invention, the drug sensitivity is low by contacting the virus inactivating agent composition having the configuration of any one of the first to sixth above with respect to the non-enveloped virus. It is an effective inactivation method for non-enveloped viruses that are difficult to inactivate.
　以下、本発明のウイルス不活性化剤組成物について詳細に説明する。ただし、本発明は、以下に説明する実施形態や実施例に記載される構成に限定されることを意図しない。 Hereinafter, the virus inactivating agent composition of the present invention will be described in detail. However, the present invention is not intended to be limited to the configurations described in the embodiments and examples described below.
　本発明のウイルス不活性化剤組成物は、（ａ）ウイルス不活性化成分として、０．０１質量％～５．０質量％のカチオン系ウイルス不活性化成分と、（ｂ）ウイルス不活性化効力増強成分として、０．０２質量％～１０．０質量％のフマル酸、リン酸、乳酸、及びクエン酸からなる群より選択される１種又は２種以上と、水と、を配合したものである。 The virus inactivating agent composition of the present invention comprises (a) a cationic virus inactivating component of 0.01% by mass to 5.0% by mass as a virus inactivating component, and (b) a virus inactivating component. A mixture of one or more selected from the group consisting of 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid, and water as an efficacy enhancing component. Is.
　本発明のウイルス不活性化剤組成物にウイルス不活性化成分として配合される（ａ）カチオン系ウイルス不活性化成分が、高いウイルス不活性化効果を有することは知られていたが、ウイルス不活性化における速効性においては検討の余地があった。今般、（ａ）カチオン系ウイルス不活性化成分と、フマル酸、リン酸、乳酸、及びクエン酸からなる群より選択される１種又は２種以上とを併用することで、ウイルス不活性化における速効性を相乗的に向上させることができたことは、本発明者らによって初めて発見された知見である。 It has been known that the (a) cationic virus inactivating component compounded as a virus inactivating component in the virus inactivating agent composition of the present invention has a high virus inactivating effect, but is virus inactivating. There was room for consideration in the rapid effect on activation. Now, by using (a) a cationic virus inactivating component in combination with one or more selected from the group consisting of fumaric acid, phosphoric acid, lactic acid, and citric acid, in virus inactivation. It is the first finding by the present inventors that the rapid effect could be improved synergistically.
　本発明のウイルス不活性化剤組成物では、ウイルス不活性化における速効性を十分に向上させるために、（ａ）ウイルス不活性化成分として、カチオン系ウイルス不活性化成分はウイルス不活性化剤組成物全体に対して０．０１質量％以上５．０質量％以下で配合される。ここで当該不活性化成分は、０．０５質量％以上３．０質量％以下で配合されることが好ましく、０．１０質量％以上１．０質量％以下で配合されることがより好ましい。 In the virus inactivating agent composition of the present invention, in order to sufficiently improve the rapid effect in virus inactivation, (a) as the virus inactivating component, the cationic virus inactivating component is the virus inactivating agent. It is blended in an amount of 0.01% by mass or more and 5.0% by mass or less with respect to the entire composition. Here, the inactivating component is preferably blended in an amount of 0.05% by mass or more and 3.0% by mass or less, and more preferably 0.10% by mass or more and 1.0% by mass or less.
　本発明のウイルス不活性化剤組成物に（ａ）ウイルス不活性化成分として配合されるカチオン系ウイルス不活性化成分としては、例えば、４級アンモニウム塩等が挙げられる。４級アンモニウム塩のカウンターアニオンとしては、特に限定されないが、フッ化物イオン（フルオライド）、塩化物イオン（クロライド）、臭化物イオン（ブロマイド）、ヨウ化物イオン（アイオダイド）、メチル硫酸イオン（メトサルフェート）、炭酸イオン（カーボネート）、重炭酸イオン（ビカーボネート）、酢酸イオン（アセテート）、プロピオン酸イオン（プロピオネート）、グルコン酸イオン（グルコネート）等が挙げられる。４級アンモニウム塩の具体例としては、１，４－ビス［３，３´－（１－デシルピリジニウム）メチルオキシ］ブタンジブロマイド、１，４－ビス［３，３´－（１－デシルピリジニウム）メチルオキシ］ブタンジクロライド、１，４－ビス［３，３´－（１－デシルピリジニウム）メチルオキシ］ブタンジメトサルフェート等の１，４－ビス［３，３´－（１－デシルピリジニウム）メチルオキシ］ブタン塩、塩化ベンザルコニウム、ベンザルコニウムメトサルフェート等のベンザルコニウム塩、塩化ベンゼトニウム、ベンゼトニウムメトサルフェート等のベンゼトニウム塩、塩化セチルピリジニウム、セチルピリジニウムメトサルフェート等のセチルピリジニウム塩、塩化ジデシルジメチルアンモニウム、デシルジメチルアンモニウムメトサルフェート等のジデシルジメチルアンモニウム塩、塩化ジラウリルジメチルアンモニウム、ジラウリルジメチルアンモニウムメトサルフェート等のジラウリルジメチルアンモニウム塩、塩化ジステアリルジメチルアンモニウム、ジステアリルジメチルアンモニウムメトサルフェート等のジステアリルジメチルアンモニウム塩、塩化ジオクチルジメチルアンモニウム等のジオクチルジメチルアンモニウム塩等のジアルキルジメチルアンモニウム塩（但し、前記アルキル基は同一又は相異なり、炭素数８～２０の直鎖飽和炭化水素を表す。）、Ｎ，Ｎ－ジデシル－Ｎ－メチルポリ（オキシエチレン）アンモニウムプロピオネート等のＮ，Ｎ－ジデシル－Ｎ－メチルポリ（オキシエチレン）アンモニウム塩、Ｎ，Ｎ－ジデシル－Ｎ，Ｎ－ジメチルアンモニウム炭酸塩／重炭酸塩、塩化Ｎ，Ｎ－ジデシル－Ｎ，Ｎ－ジメチルアンモニウム、クロルヘキシジングルコン酸塩、クロルヘキシジン塩酸塩等のクロルヘキシジン塩、塩化オクタデシルジメチル（３－トリエトキシシリルプロピル）アンモニウム、塩化ドデシルジメチル（３－トリエトキシシリルプロピル）アンモニウム、塩化ドデシルジイソプロピル（３－トリエトキシシリルプロピル）アンモニウム、塩化テトラデシルジメチル（３－トリエトキシシリルプロピル）アンモニウム、塩化テトラデシルジエチル（３－トリエトキシシリルプロピル）アンモニウム、塩化テトラデシルジ－ｎ－プロピル（３－トリエトキシシリルプロピル）アンモニウム、塩化ペンタデシルジメチル（３－トリエトキシシリルプロピル）アンモニウム、塩化ペンタデシルジエチル（３－トリエトキシシリルプロピル）アンモニウム、塩化ペンタデシルジ－ｎ－プロピル（３－トリエトキシシリルプロピル）アンモニウム、塩化ヘキサデシルジメチル（３－トリエトキシシリルプロピル）アンモニウム、塩化ヘキサデシルジエチル（３－トリエトキシシリルプロピル）アンモニウム、塩化ヘキサデシルジ－ｎ－プロピル（３－トリエトキシシリルプロピル）アンモニウム、塩化オクタデシルジエチル（３－トリエトキシシリルプロピル）アンモニウム、塩化オクタデシルジ－ｎ－プロピル（３－トリエトキシシリルプロピル）アンモニウム等のトリアルキル（３－トリエトキシシリルプロピル）アンモニウム塩（但し、前記アルキル基は同一又は相異なり、炭素数１～１８の直鎖飽和炭化水素を表わす。）等が挙げられる。これらのカチオン系ウイルス不活性化成分は単独で用いても良いし、２種以上を混合して用いても良い。 Examples of the cationic virus inactivating component blended as the (a) virus inactivating component in the virus inactivating agent composition of the present invention include a quaternary ammonium salt and the like. The counter anion of the quaternary ammonium salt is not particularly limited, but is limited to fluoride ion (fluoride), chloride ion (chloride), bromide ion (bromide), iodide ion (iodide), methyl sulfate ion (methosulfate), and the like. Examples thereof include carbonate ion (carbonate), bicarbonate ion (bicarbonate), acetate ion (acetate), propionate ion (propionate), and gluconate ion (gluconate). Specific examples of the quaternary ammonium salt include 1,4-bis [3,3'-(1-decylpyridinium) methyloxy] butanjibromide and 1,4-bis [3,3'-(1-decylpyridinium). ) Methyloxy] butanedichloride, 1,4-bis [3,3'-(1-decylpyridinium) methyloxy] butanjimethosulfate, etc. 1,4-bis [3,3'-(1-decylpyridinium) Methyloxy] Butane salt, benzalconium chloride, benzalkonium salt such as benzalconium metosulfate, benzethonium chloride, benzethonium such as benzethonium metosulfate, cetylpyridinium salt such as cetylpyridinium chloride, cetylpyridiniummethsulfate, dichloride Didecyldimethylammonium salts such as decyldimethylammonium and decyldimethylammonium metosulfate, dilauryldimethylammonium salts such as dilauryldimethylammonium chloride and dilauryldimethylammonium metosulfate, distearyldimethylammonium chloride, distearyldimethylammonium metosulfate and the like. Dialkyldimethylammonium salt such as dioctyldimethylammonium salt such as distearyldimethylammonium salt and dioctyldimethylammonium chloride (however, the alkyl group represents the same or different linear saturated hydrocarbon having 8 to 20 carbon atoms). , N, N-didecil-N-methylpoly (oxyethylene) ammonium salt such as N, N-didecil-N-methylpoly (oxyethylene) ammonium propionate, N, N-didecil-N, N-dimethylammonium carbonate / Chlorhexidine salts such as bicarbonate, N, N-didecyl-N, N-dimethylammonium, chlorhexizing luconate, chlorhexidine hydrochloride, octadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, dodecyldimethyl chloride (3) -Triethoxysilylpropyl) ammonium, dodecyldiisopropyl (3-triethoxysilylpropyl) ammonium chloride, tetradecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, tetradecyldiethyl (3-triethoxysilylpropyl) ammonium chloride, chloride Tetradecyldi-n-propyl (3-triethoxysilylpropyl) ammonium, pentadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride , Pentadecyldiethyl chloride (3-triethoxysilylpropyl) ammonium, pentadecyldi-n-propyl (3-triethoxysilylpropyl) ammonium chloride, hexadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, hexadecyldiethyl chloride (3-triethoxysilylpropyl) ammonium 3-Triethoxysilylpropyl) ammonium, hexadecyldi-n-propyl chloride (3-triethoxysilylpropyl) ammonium, octadecyldiethyl chloride (3-triethoxysilylpropyl) ammonium, octadecyldi-n-propyl chloride (3-triethoxy) Trialkyl (3-triethoxysilylpropyl) ammonium salts such as silylpropyl) ammonium (provided that the alkyl groups are the same or different and represent linear saturated hydrocarbons having 1 to 18 carbon atoms. ) Etc. can be mentioned. These cationic virus inactivating components may be used alone or in combination of two or more.
　上記カチオン系ウイルス不活性化成分の中でも、ウイルス不活性化における速効性を向上させ得る観点から、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイド、塩化ベンザルコニウム、塩化ベンゼトニウム、塩化ジデシルジメチルアンモニウム、クロルヘキシジングルコン酸塩及び塩化オクタデシルジメチル（３－トリエトキシシリルプロピル）アンモニウムを用いることが好ましく、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイドを用いることがより好ましい。 Among the above cationic virus inactivating components, 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butane dibromide, chloride, from the viewpoint of improving the rapid effect in virus inactivation. It is preferable to use benzalkonium, benzethonium chloride, didecyldimethylammonium chloride, chlorhexidine gluconate and octadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride, 1,4-bis (3,3'-(1-). It is more preferable to use decylpyridinium) methyloxy) butane dibromide.
　本発明のウイルス不活性化剤組成物に（ｂ）ウイルス不活性化効力増強成分として配合される有機酸及び／又は無機酸としては、フマル酸、リン酸、乳酸、クエン酸からなる群より選択される１種又は２種以上が挙げられ、フマル酸、リン酸、乳酸からなる群より選択される１種又は２種以上が好ましく、フマル酸及び／又はリン酸が好ましい。これらの有機酸及び／又は無機酸を用いることで、ウイルス不活性化成分であるカチオン系ウイルス不活性化成分が低い配合量でも、ウイルス不活性化における速効性をより顕著に向上させることができる。これら有機酸及び／又は無機酸は単独で用いても良いし、２種以上を混合して用いても良い。 The organic acid and / or the inorganic acid to be blended in the virus inactivating agent composition of the present invention as (b) a component for enhancing the virus inactivating efficacy is selected from the group consisting of fumaric acid, phosphoric acid, lactic acid and citric acid. One or more of them are mentioned, and one or more selected from the group consisting of fumaric acid, phosphoric acid and lactic acid is preferable, and fumaric acid and / or phosphoric acid is preferable. By using these organic acids and / or inorganic acids, the rapid effect on virus inactivation can be more significantly improved even when the amount of the cationic virus inactivating component, which is a virus inactivating component, is low. .. These organic acids and / or inorganic acids may be used alone or in combination of two or more.
　本発明のウイルス不活性化剤組成物のｐＨは１～６が望ましい。これにより、ウイルス不活性化剤組成物が酸性～弱酸性となり、アルカリ性のウイルス不活性化剤に比べて皮膚に対する腐食性もなく、使用感に優れたウイルス不活性化剤組成物となる。 The pH of the virus inactivating agent composition of the present invention is preferably 1 to 6. As a result, the virus inactivating agent composition becomes acidic to weakly acidic, and the virus inactivating agent composition is less corrosive to the skin than the alkaline virus inactivating agent and has an excellent usability.
　本発明のウイルス不活性化剤組成物における（ｂ）ウイルス不活性化効力増強成分の配合量は、特に限定されないものの、配合量が少なすぎる場合は、カチオン系ウイルス不活性化成分のウイルス不活性化における速効性を十分に向上させる効果が得られない可能性がある。 The blending amount of the (b) virus inactivating efficacy enhancing component in the virus inactivating agent composition of the present invention is not particularly limited, but if the blending amount is too small, the virus inactivation of the cationic virus inactivating component is performed. There is a possibility that the effect of sufficiently improving the quick-acting effect of the virus cannot be obtained.
　後述の実施例に示すように、ウイルス不活性化における速効性を十分に向上させるためには、（ｂ）ウイルス不活性化効力増強成分である有機酸及び／又は無機酸はウイルス不活性化剤組成物に対して０．０２質量％以上１０．０質量％以下で配合され、０．０３質量％以上５．０質量％以下であることが好ましく、０．１０質量％以上２．０質量％以下であることがより好ましい。 As shown in Examples described later, in order to sufficiently improve the rapid effect in virus inactivation, (b) an organic acid and / or an inorganic acid which is a virus inactivating efficacy enhancing component is a virus inactivating agent. It is blended in an amount of 0.02% by mass or more and 10.0% by mass or less with respect to the composition, preferably 0.03% by mass or more and 5.0% by mass or less, and 0.10% by mass or more and 2.0% by mass or less. The following is more preferable.
　本発明のウイルス不活性化剤組成物において、（ａ）ウイルス不活性化成分と（ｂ）ウイルス不活性化効力増強成分の配合質量比（ａ）／（ｂ）は、０．００１≦（ａ）／（ｂ）≦２５０であり、０．００５≦（ａ）／（ｂ）≦１００であることが好ましく、０．０１≦（ａ）／（ｂ）≦５０であることがより好ましく、これにより、ウイルス不活性化における速効性をより向上させることができるウイルス不活性化剤組成物となる。 In the virus inactivating agent composition of the present invention, the compounding mass ratio (a) / (b) of (a) the virus inactivating component and (b) the virus inactivating efficacy enhancing component is 0.001 ≦ (a). ) / (B) ≤ 250, preferably 0.005 ≤ (a) / (b) ≤ 100, and more preferably 0.01 ≤ (a) / (b) ≤ 50. This results in a virus inactivating agent composition capable of further improving the rapid effect on virus inactivation.
　本発明のウイルス不活性化剤組成物には、さらに（ｃ）エタノールを１０質量％～８０質量％配合することが好ましい。（ｃ）エタノールを１０質量％～８０質量％配合することにより、ウイルス不活性化における速効性を向上させることができる。また、ウイルス不活性化剤組成物の揮散性も向上することから、速乾性に優れるウイルス不活性化剤組成物となる。中でも、（ｃ）エタノールを３５質量％～６５質量％配合することがより好ましく、（ｃ）エタノール５５質量％～６５質量％配合することがさらに好ましい。これらの配合量とすることにより、ウイルス不活性化における速効性をより効果的に向上させることができ、使用時に皮膚刺激が出にくく、さらにウイルス不活性化剤組成物の揮散性も効果的に向上することから、速乾性に優れるウイルス不活性化剤組成物となる。 It is preferable that the virus inactivating agent composition of the present invention further contains (c) ethanol in an amount of 10% by mass to 80% by mass. (C) By blending 10% by mass to 80% by mass of ethanol, the rapid effect on virus inactivation can be improved. Further, since the volatility of the virus inactivating agent composition is also improved, the virus inactivating agent composition having excellent quick-drying property is obtained. Above all, (c) ethanol is more preferably blended in an amount of 35% by mass to 65% by mass, and (c) ethanol is further preferably blended in an amount of 55% by mass to 65% by mass. By using these amounts, the rapid effect on virus inactivation can be more effectively improved, skin irritation is less likely to occur during use, and the volatilization of the virus inactivating agent composition is also effective. Since it is improved, it becomes a virus inactivating agent composition having excellent quick-drying property.
　本発明のウイルス不活性化剤組成物には、必要に応じて界面活性剤を配合することができる。例えば、界面活性剤には泡を発生する性質（泡立ち性）があるため、泡立ち性に優れた界面活性剤を使用すれば、本発明のウイルス不活性化剤組成物をトリガースプレー等で壁面にスプレーしたときの液ダレを抑制するとともに塗布領域も視認しやすくなるというメリットを有する。 A surfactant can be added to the virus inactivating agent composition of the present invention, if necessary. For example, since the surfactant has a property of generating bubbles (foaming property), if a surfactant having excellent foaming property is used, the virus inactivating agent composition of the present invention can be applied to the wall surface by a trigger spray or the like. It has the advantage of suppressing liquid dripping when sprayed and making it easier to see the coated area.
　本発明のウイルス不活性化剤組成物に配合される界面活性剤としては、アニオン界面活性剤、ノニオン界面活性剤、両性界面活性剤のいずれも好適に用いられる。本発明のウイルス不活性化剤組成物中における界面活性剤の配合量は、特に限定されないものの、０．１質量％以上１０質量％以下であることが好ましい。なお、本発明のウイルス不活性化剤組成物に配合されるカチオン系ウイルス不活性化成分は、本明細書中では界面活性剤には含めないこととする。 As the surfactant to be blended in the virus inactivating agent composition of the present invention, any of anionic surfactant, nonionic surfactant and amphoteric surfactant is preferably used. The blending amount of the surfactant in the virus inactivating agent composition of the present invention is not particularly limited, but is preferably 0.1% by mass or more and 10% by mass or less. The cationic virus inactivating component contained in the virus inactivating agent composition of the present invention is not included in the surfactant in the present specification.
　アニオン界面活性剤の例としては、例えば脂肪酸石けん、アルキルベンゼンスルホン酸塩、直鎖アルキルベンゼンスルホン酸塩、アルキル硫酸塩、α―オレフィンスルホン酸塩、アルキルリン酸エステル塩、ポリオキシエチレンアルキルエーテル硫酸塩、ポリオキシエチレンアルキルフェニルエーテル硫酸塩、ポリオキシエチレンアルキルエーテルリン酸塩などが挙げられる。 Examples of anionic surfactants include fatty acid soaps, alkylbenzene sulfonates, linear alkylbenzene sulfonates, alkyl sulfates, α-olefin sulfonates, alkyl phosphate ester salts, polyoxyethylene alkyl ether sulfates, etc. Examples thereof include polyoxyethylene alkyl phenyl ether sulfate and polyoxyethylene alkyl ether phosphate.
　ノニオン界面活性剤の例としては、例えばポリオキシエチレンアルキルエーテル、ポリオキシエチレンアルキルフェニルエーテル、ポリオキシエチレン高級脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレングリセリン脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油、ヤシ油脂肪酸ジエタノールアミド、ポリオキシエチレンポリオキシプロピレンアルキルエーテル、脂肪酸アルカノールアミド、アルキルアミンオキシドなどが挙げられる。 Examples of nonionic surfactants include polyoxyethylene alkyl ethers, polyoxyethylene alkyl phenyl ethers, polyoxyethylene higher fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene glycerin fatty acid esters, and polyoxyethylene hydrogenated castor oil. , Palm oil fatty acid diethanolamide, polyoxyethylene polyoxypropylene alkyl ether, fatty acid alkanolamide, alkylamine oxide and the like.
　両性界面活性剤の例としては、ベタイン型界面活性剤が挙げられる。具体的には、ラウリル－Ｎ，Ｎ－ジメチル酢酸ベタイン、ラウリルアミドプロピル－Ｎ，Ｎ－ジメチル酢酸ベタイン、ヤシアルキルアミドプロピル－Ｎ，Ｎ－ジメチルヒドロキシプロピルスルホベタイン等が挙げられる。 Examples of amphoteric surfactants include betaine-type surfactants. Specific examples thereof include lauryl-N, N-dimethylacetate betaine, laurylamide propyl-N, N-dimethylacetate betaine, coconut alkylamide propyl-N, N-dimethylhydroxypropyl sulfobetaine and the like.
　本発明のウイルス不活性化剤組成物は、水系タイプであり、溶媒としては主に水が用いられる。水としては、イオン交換水や逆浸透膜水等の精製水や、通常の水道水や工業用水、海洋深層水等が挙げられる。 The virus inactivating agent composition of the present invention is an aqueous type, and water is mainly used as the solvent. Examples of water include purified water such as ion-exchanged water and reverse osmosis membrane water, ordinary tap water, industrial water, and deep ocean water.
　更に、本発明のウイルス不活性化剤組成物には、その他の成分として、必要に応じて、カチオン系ウイルス不活性化成分以外の抗菌、ウイルス不活性化剤、防藻剤、防錆剤、溶剤、キレート剤、香料、消臭成分、ｐＨ調整剤、保湿成分、増粘剤等を、本発明の効果を損なわない範囲で配合することにより、抗菌効果、ウイルス不活性化効果、防藻効果、防錆効果、洗浄効果、芳香性、消臭性、保湿効果、増粘効果等を付与するようにしてもよい。 Further, in the virus inactivating agent composition of the present invention, as other components, as necessary, antibacterial agents other than cationic virus inactivating components, virus inactivating agents, algae-proofing agents, rust-preventing agents, etc. By blending a solvent, a chelating agent, a fragrance, a deodorant component, a pH adjuster, a moisturizing component, a thickener, etc. within a range that does not impair the effects of the present invention, an antibacterial effect, a virus inactivating effect, an algae-proofing effect, etc. , Anti-corrosion effect, cleaning effect, fragrance, deodorant property, moisturizing effect, thickening effect and the like may be imparted.
　他の抗菌、ウイルス不活性化剤の例としては、イソプロピルメチルフェノール（ＩＰＭＰ）、カルバクロール、チモール、トリクロサン、メチルパラベン、エチルパラベン、プロピルパラベン、ブチルパラベン、４－クロロ－３,５－ジメチルフェノール、オルトフェニルフェノール、о－クレゾール、ｍ－クレゾール、ｐ－クレゾール、テブコナゾール、エニルコナゾール、グレープフルーツ種子抽出物、カキ種子抽出物、ブドウ種子抽出物、モノラウリン、モノカプリン、モノカプリリン、安息香酸、ソルビン酸、グリシン、アルキルジエチルアミノグリシン、ポリリジン、デヒドロ酢酸、デヒドロ酢酸ナトリウム、クロラミン、３－ヨード－２－プロピル－Ｎ－ブチルカルバメート（ＩＰＢＣ）、フェノキシエタノール、銀ゼオライト、ジンクピリチオン、チアミンラウリル硫酸塩、白子たんぱく質、ヒドロキシアルキルキトサン、キトサン等が挙げられる。 Examples of other antibacterial and virus inactivating agents include isopropylmethylphenol (IPMP), carbacrol, thymol, triclosan, methylparaben, ethylparaben, propylparaben, butylparaben, 4-chloro-3,5-dimethylphenol, Orthophenylphenol, о-cresol, m-cresol, p-cresol, tebuconazole, enilconazole, grapefruit seed extract, oyster seed extract, grape seed extract, monolaurin, monocaprin, monocapriline, benzoic acid, sorbic acid, Glycin, Alkyldiethylaminoglycine, Polylysine, Dehydroacetic acid, Sodium dehydroacetate, Chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), Phenoxyethanol, Silver zeolite, Zincpyrythion, Thymol lauryl sulfate, Shirako protein, Hydroxyalkyl Examples include thymol and thymol.
　防藻剤の例としては、ジクロロイソシアヌル酸ナトリウム等が挙げられる。防錆剤の例としては、安息香酸ナトリウム等が挙げられる。 Examples of anti-algae agents include sodium dichloroisocyanurate. Examples of rust preventives include sodium benzoate and the like.
　溶剤の例としては、ノルマルパラフィン、イソパラフィン、流動パラフィン、ナフテン系炭化水素、ワセリン、スクワラン、α－オレフィンオリゴマー等の炭化水素系溶剤、１－プロパノール、２－プロパノール（ＩＰＡ）、１－ブタノール、２－ブタノール、ターシャリーブタノール、１－ペンタノール、１－ヘキサノール、ベンジルアルコール、２－フェニルエタノール等のアルコール系溶剤、２－フェノキシエタノール（エチレングリコールモノフェニルエーテル）、エチレングリコール、プロピレングリコール、１－フェノキシ－２－プロパノール（プロピレングリコールフェニルエーテル）、１，３－ブチレングリコール、プロピレングリコールモノブチルエーテル、ジプロピレングリコールモノブチルエーテル、トリプロピレングリコールモノブチルエーテル等のグリコール系溶剤等が挙げられる。 Examples of the solvent include normal paraffin, isoparaffin, liquid paraffin, naphthenic hydrocarbon, vaseline, squalane, hydrocarbon solvent such as α-olefin oligomer, 1-propanol, 2-propanol (IPA), 1-butanol, 2 -Alcohol solvents such as butanol, tertiary butanol, 1-pentanol, 1-hexanol, benzyl alcohol, 2-phenylethanol, 2-phenoxyethanol (ethylene glycol monophenyl ether), ethylene glycol, propylene glycol, 1-phenoxy- Examples thereof include glycol-based solvents such as 2-propanol (propylene glycol phenyl ether), 1,3-butylene glycol, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, and tripropylene glycol monobutyl ether.
　香料の例としては、ｄ－リモネン等のリモネン、α－ピネン、β－ピネン等のピネン、ｐ－シメン等のシメン、インデン、カリオフィレン等の炭化水素系香料、リナロール、ゲラニオール、シトロネロール、ｌ－メントール等のメントール、エチルリナロール、ボルネオール、アニスアルコール、β－フェネチルアルコール、ｐ－メンタン－３、８－ジオール、α－テルピネオール、γ－テルピネオール等のテルピネオール、１－ヘキセノール、シス－３－ヘキセン－１－オール、テトラヒドロゲラニオール、サンタリノール、シンナミルアルコール、セドロール等のアルコール系香料、ガラクソリド、β－ナフチルメチルエーテル、シネオール、アンブロキシド、ｐ－クレジールメチルエーテル等のエーテル系香料、アネトール、オイゲノール、イソオイゲノール、バニリン、エチルバニリン等のフェノール系香料、オクタナール、ノナナール、ウンデシルアルデヒド、ウンデカナール、デシルアルデヒド、ｎ－ブチルアルデヒド、イソブチルアルデヒド、ヘキシルアルデヒド、シトラール、シトロネラール、ベンズアルデヒド、シンナミックアルデヒド、アニスアルデヒド、クミンアルデヒド、アドキサール、アミルシンナミックアルデヒド、シクラメンアルデヒド等のアルデヒド系香料、ムスクケトン、カルボン、メントン、樟脳、カンファー、アセトフェノン、ブチロフェノン、トナリド、α－イオノン、β－イオノン、α－メチルイオノン、β－メチルイオノン、α－イソメチルイオノン、β－イソメチルイオノン、γ－メチルイオノン、γ－イソメチルイオノン、ダマスコン、α－ダマスコン、β－ダマスコン、アセチルセドレン、カシュメラン、シスジャスモン、ジヒドロジャスモン等のケトン系香料、γ－ブチルラクトン、γ－ノナラクトン、γ－デカラクトン、γ－ウンデカラクトン、クマリン、シネオール、アンブレットリッド、ジャスモラクトン等のラクトン系香料、ゲラニルフォーメート、オクチルアセテート、ゲラニルアセテート、ベンジルアセテート、シンナミルアセテート、テトラヒドロゲラニルアセテート、酢酸メンチル、酢酸リナリル、プロピオン酸ブチル、酢酸ベンジル、安息香酸メチル、アリルヘキサノエート、アリルヘプタノエート、アリルシクロヘキサンプロピオネート、アリルアミルグリコレート、アミルバレリアネート、アミルサリシレート、イソアミルアセテート、ブチルアセテート、エチルブチレート、アセチルオイゲノール、イソアミルサリシレート、アリルカプロエート、エチルカプロエート、エチルプロピオネート、エチルアセトアセテート、メチルサリシレート、シトロネリルアセテート、シトロネリルフォーメート、シンナミルアセテート、ステアリルアセテート、ステアリルプロピオネート、セドリルアセテート、ターピニルアセテート等のエステル系香料、アミルシンナミックアルデヒドジメチルアセタール、シトラールジメチルアセタール等アセタール系香料、インドール、ゲラニルニトリル、シトロネリルニトリル、アセトアルデヒドフェニルエチルプロピルアセテート、テサロン、オウランチオール、リナロールオキシド、ハッカ油、オレンジ油、レモン油、ラベンダー油、ペパーミント油、ユーカリ油、シトロネラ油、ライム油、ユズ油、ジャスミン油、檜油、緑茶精油、ネロリ油、ゼラニウム油、プチグレン油、レモングラス油、シナモン油、レモンユーカリ油、タイム油、ペリラ油、パイン油、ローズ油、ローズマリー油、しょう脳油、芳油、クラリーセージ油、サンダルウッド油、スペアミント油、スターアニス油、ラバンジン油、オークモス油、オコチア油、パチュリ油、トンカ豆チンキ、テレピン油、ワニラ豆チンキ、バジル油、ナツメグ油、クローブ油、ボアドローズ油、カナンガ油、カルダモン油、カシア油、シダーウッド油、マンダリン油、タンジェリン油、アニス油、ベイ油、コリアンダー油、エレミ油、フェンネル油、ガルバナム油、ヒバ油、ベチバー油、ベルガモット油、イランイラン油、グレープフルーツ油、アビエス油、アクジョン油、アルモンド油、アンゲリカルート油、ページル油、ミント油、パーチ油、ボアバローズ油、カヤブチ油、ガナンガ油、カプシカム油、キャラウェー油、セロリー油、コニャック油、クミン油、ジル油、エストゴラン油、ガーリック油、ジンジャー油、ホップ油、セージ油、テレピン油等が挙げられる。 Examples of fragrances include limonene such as d-lymonen, pinen such as α-pinen and β-pinen, simen such as p-simene, hydrocarbon fragrances such as inden and cariophyllene, linalol, geraniol, citronellol, and l-menthol. Mentor, ethyllinalol, borneol, anis alcohol, β-phenethyl alcohol, p-menthan-3,8-diol, α-terpineol, γ-terpineol such as terpineol, 1-hexenol, cis-3-hexene-1- Alcohol-based fragrances such as oar, tetrahydrogeraniol, santalinol, cinnamyl alcohol, and sedrol, ether-based fragrances such as galaxolide, β-naphthylmethyl ether, cineol, ambroxide, and p-cresylmethyl ether, anetol, eugenol, and isooigenol. , Vanillin, Ethylvanylin and other phenolic fragrances, octanal, nonanal, undecylaldehyde, undecanal, decylaldehyde, n-butylaldehyde, isobutylaldehyde, hexylaldehyde, citral, terpineol, benzaldehyde, cinnamic aldehyde, anisaldehyde, cumin Aldehyde-based fragrances such as aldehydes, adxal, amilcinnamic aldehydes, and cyclamen aldehydes, muskketones, carboxylics, mentons, cerebral brains, camphor, acetophenone, butyrophenone, tonalide, α-ionone, β-ionone, α-methylionone, β-methylionone, α -Ketone-based fragrances such as isomethylionone, β-isomethylionone, γ-methylionone, γ-isomethylionone, damascon, α-damascon, β-damascon, acetylsedrene, cashmeren, cis jasmon, dihydrojasmon, etc. , Gamma-butyl lactone, γ-nonalactone, γ-decalactone, γ-undecalactone, coumarin, cineol, ambret lid, jasmolactone and other lactone-based fragrances, geranylformate, octylacetate, geranylacetate, benzylacetate, Synamyl acetate, tetrahydrogeranyl acetate, menthyl acetate, linaryl acetate, butyl propionate, benzyl acetate, methyl benzoate, allylhexanoate, allylheptanoate, allylcyclohexanepropionate, allylamylglycolate, amylvalerianate, Amil salicylate, isoamyl acetate, bu Chill acetate, ethyl butyrate, acetyl eugenol, isoamyl salicylate, allyl caproate, ethyl caproate, ethyl propionate, ethyl acet acetate, methyl salicylate, citronellyl acetate, citronellyl formate, cinnamyl acetate, stearyl acetate , Stearyl propionate, sedrill acetate, turpinyl acetate and other ester fragrances, amilcinnamic aldehyde dimethyl acetal, citral dimethyl acetal and other acetal fragrances, indole, geranyl nitrile, citronellyl nitrile, acetaldehyde phenyl ethyl propyl acetate, Tesalon, aulanthiol, linalol oxide, peppermint oil, orange oil, lemon oil, lavender oil, peppermint oil, eucalyptus oil, citronella oil, lime oil, yuzu oil, jasmine oil, cypress oil, green tea essential oil, neroli oil, geranium oil, Petit grain oil, lemongrass oil, cinnamon oil, lemon eucalyptus oil, thyme oil, perilla oil, pine oil, rose oil, rosemary oil, ginger brain oil, fragrant oil, clary sage oil, sandalwood oil, spare mint oil, star anis oil , Labandin oil, oak moss oil, okotia oil, patchouli oil, tonka bean tincture, terepine oil, crocodile bean tincture, basil oil, nutmeg oil, clove oil, boadrose oil, cananga oil, cardamon oil, cassia oil, cedarwood oil, mandarin oil , Tangerine oil, Anis oil, Bay oil, Coriander oil, Elemi oil, Fennel oil, Galvanum oil, Hiba oil, Vetiba oil, Bergamot oil, Iran Iran oil, Grapefruit oil, Abies oil, Akjong oil, Almond oil, Angelica root oil , Pagel oil, mint oil, perch oil, boa barrose oil, kayabuchi oil, gananga oil, capsicum oil, caraway oil, celery oil, cognac oil, cumin oil, jill oil, estgolan oil, garlic oil, ginger oil, hop oil, Examples include sage oil and terepine oil.
　消臭成分の例としては、サトウキビエキス、緑茶抽出エキス、チャ乾留物、柿抽出エキス、グレープフルーツ抽出エキス、モウゾウチク抽出エキス、ユズ種子抽出エキス、レンギョウ抽出エキス等が挙げられるが、消臭効果に加えて、ノロウイルス不活性化作用を助長する観点から、サトウキビエキスが好適である。 Examples of deodorant components include sugar cane extract, green tea extract, cha dry distillate, persimmon extract, grapefruit extract, mozochiku extract, yuzu seed extract, and lotus extract, but in addition to the deodorizing effect. Therefore, sugar cane extract is suitable from the viewpoint of promoting the inactivating action of norovirus.
　ｐＨ調整剤の例としては、酢酸、リンゴ酸、サリチル酸等の他の有機酸、塩酸等の他の無機酸、クエン酸ナトリウム、炭酸ナトリウム、炭酸水素ナトリウム、水酸化ナトリウム等が挙げられる。 Examples of the pH adjuster include other organic acids such as acetic acid, malic acid and salicylic acid, other inorganic acids such as hydrochloric acid, sodium citrate, sodium carbonate, sodium hydrogencarbonate, sodium hydroxide and the like.
　保湿成分の例としては、グリセリンやプロピレングリコール、１，３ーブチレングリコールなどのグリコール類、ソルビトールなどの多価アルコール類が挙げられる。 Examples of moisturizing ingredients include glycols such as glycerin, propylene glycol and 1,3-butylene glycol, and polyhydric alcohols such as sorbitol.
　増粘剤の例としては、架橋型ポリアクリル酸であるカルボキシビニルポリマーや、カルボキシメチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプピルセルロースなどのセルロース誘導体、キサンタンガム、グアーガム、アラビアガム、アルギン酸ナトリウム、アルギン酸プロピレングリコール、エチルセルロース、ポリアクリル酸ナトリウム、シクロデキストリン等が挙げられる。 Examples of thickeners include carboxyvinyl polymers, which are cross-linked polyacrylic acids, cellulose derivatives such as carboxymethyl cellulose, hydroxyethyl cellulose, and hydroxypupyl cellulose, xanthan gum, guar gum, arabic gum, sodium alginate, propylene glycol alginate, and ethyl cellulose. , Sodium polyacrylate, cyclodextrin and the like.
　こうして得られた本発明のウイルス不活性化剤組成物を、ウイルス感染者が触れた場所、ウイルス感染者の嘔吐物を処理した場所、衣服等のウイルスで汚染された場所に塗布あるいはスプレーすることで、ウイルスを効果的に除去することができる。 The virus inactivating agent composition of the present invention thus obtained is applied or sprayed to a place touched by a virus-infected person, a place where a virus-infected person's vomit is treated, or a place contaminated with a virus such as clothes. Therefore, the virus can be effectively removed.
　また、本発明のウイルス不活性化剤組成物を手指等に塗布あるいはスプレーすることで、手指等に付着したウイルスを効果的に除去し、手指の消毒をすることができる。 Further, by applying or spraying the virus inactivating agent composition of the present invention on the fingers or the like, the virus adhering to the fingers or the like can be effectively removed and the fingers or the like can be disinfected.
　また、本発明のウイルス不活性化組成物は、インフルエンザウイルス、コロナウイルス、ヘルペスウイルス等のエンベロープウイルスに加えて、ノロウイルス、ロタウイルス、ライノウイルス、アデノウイルス等のノンエンベロープウイルスに対しても高い不活性化効果を有する。従って、従来のウイルス除去剤では不活性化が困難であったノロウイルスの不活性化にも好適に使用することができる。 Further, the virus inactivating composition of the present invention is highly resistant to enveloped viruses such as influenza virus, coronavirus and herpesvirus, as well as non-enveloped viruses such as norovirus, rotavirus, rhinovirus and adenovirus. Has an activating effect. Therefore, it can also be suitably used for inactivating norovirus, which was difficult to inactivate with conventional virus removing agents.
　また、本発明のウイルス不活性化剤組成物は、ウイルス不活性化成分としての、カチオン系ウイルス不活性化成分と、ウイルス不活性化効力増強成分としての、特定の有機酸および／又は無機酸とを水に配合するだけで構成され、非常に単純な組成である。そのため、製造が簡便である。また、銀イオンによる変色の問題もないため、使用性にも優れている。 In addition, the virus inactivating agent composition of the present invention comprises a cationic virus inactivating component as a virus inactivating component and a specific organic acid and / or an inorganic acid as a virus inactivating efficacy enhancing component. It is a very simple composition that consists only of adding and to water. Therefore, it is easy to manufacture. In addition, since there is no problem of discoloration due to silver ions, it is also excellent in usability.
　なお、本発明は上述した実施形態に限定されるものではなく、請求項に示した範囲で種々の変更が可能であり、異なる実施形態にそれぞれ開示された技術的手段を適宜組み合わせて得られる実施形態についても本発明の技術的範囲に含まれる。以下、実施例により本発明の効果について更に具体的に説明するが、本発明はこれらの実施例に制約されるものではない。 The present invention is not limited to the above-described embodiment, and various modifications can be made within the scope of the claims, and the invention can be obtained by appropriately combining the technical means disclosed in the different embodiments. The form is also included in the technical scope of the present invention. Hereinafter, the effects of the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.
［試験液の調製］
　（ａ）１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイド（ハイジェニアＳ－１００、タマ化学工業株式会社製）、塩化ベンザルコニウム（カチオンＦ２－５０Ｒ、日油株式会社製）、塩化ベンゼトニウム（富士フイルム和光純薬株式会社製）、塩化ジデシルジメチルアンモニウム（リポガード２１０－８０Ｅ、ライオン・スペシャリティ・ケミカルズ株式会社製）、２０％クロルヘキシジングルコン酸塩水溶液（富士フイルム和光純薬株式会社製）、（ｂ）フマル酸、リン酸、乳酸、クエン酸一水和物（以上、富士フイルム和光純薬株式会社製）、（ｃ）エタノールを表１、表３に示す配合割合（質量％）で配合し、精製水を加えて１００質量％として試験液（本発明１～２１）を得た。 [Preparation of test solution]
(A) 1,4-Bis (3,3'-(1-decylpyridinium) methyloxy) butanjibromide (Hygenia S-100, manufactured by Tama Kagaku Kogyo Co., Ltd.), benzalkonium chloride (cation F2-50R, Benzalkonium chloride (manufactured by Fuji Film Wako Pure Chemical Industries, Ltd.), Didecyldimethylammonium chloride (Lipogard 210-80E, manufactured by Lion Specialty Chemicals Co., Ltd.), 20% chlorhexizing luconate aqueous solution (Fuji) (B) Fumaric acid, phosphoric acid, lactic acid, citrate monohydrate (above, manufactured by Fujifilm Wako Junyaku Co., Ltd.), (c) Ethanol are shown in Tables 1 and 3. The mixture was blended in the indicated blending ratio (% by mass), and purified water was added to make 100% by mass to obtain a test solution (1 to 21 of the present invention).
　（ａ）１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイド（ハイジェニアＳ－１００、タマ化学工業株式会社製）、塩化ベンザルコニウム（カチオンＦ２－５０Ｒ、日油株式会社製）、塩化ベンゼトニウム（富士フイルム和光純薬株式会社製）、塩化ジデシルジメチルアンモニウム（リポガード２１０－８０Ｅ、ライオン・スペシャリティ・ケミカルズ株式会社製）、イソプロピルメチルフェノール（富士フイルム和光純薬株式会社製）、（ｂ）フマル酸、リン酸、乳酸（以上、富士フイルム和光純薬株式会社製）、（ｃ）エタノールを表２、表４に示す配合割合（質量％）で配合し、精製水を加えて１００質量％として試験液（比較例１～１５）を得た。 (A) 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butanjibromide (Hygenia S-100, manufactured by Tama Kagaku Kogyo Co., Ltd.), benzalkonium chloride (cation F2-50R, Benzalkonium chloride (manufactured by Wako Pure Chemical Industries, Ltd.), Didecyldimethylammonium chloride (Lipogard 210-80E, manufactured by Lion Specialty Chemicals Co., Ltd.), Isopropylmethylphenol (manufactured by Wako Pure Chemical Industries, Ltd.) (B) Fumaric acid, phosphoric acid, lactic acid (all manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), (c) Ethanol are blended in the blending ratios (% by mass) shown in Tables 2 and 4. Purified water was added to make 100% by mass, and test solutions (Comparative Examples 1 to 15) were obtained.
［ウイルス不活性化効果の確認試験１（Feline　calicivirus）］
（試験ウイルス液の調製）
　ＭＥＭ培地（ナカライテスク株式会社製）に牛胎仔血清を１０％加えた細胞増殖培地を用いてＣＲＦＫ細胞（ＪＣＲＢ細胞バンク）を組織培養シャーレ内に単層培養した。単層培養シャーレ内から細胞増殖培地を除去し、ネコカリシウイルス（Feline　calicivirus　F-9　ATCC　VR-782）を接種した。次に、ＭＥＭ培地に牛胎仔血清を２％加えた細胞維持培地を加えて３７±１℃の炭酸ガスインキュベーター（ＣＯ２濃度５％）内で１～５日間培養した。ネコカリシウイルスはノンエンベロープウイルスの一種であり、細胞培養できないノロウイルスの代替ウイルスとして広く使用されている。 [Confirmation test 1 of virus inactivating effect (Feline calicivirus)]
(Preparation of test virus solution)
CRFK cells (JCRB cell bank) were monolayer-cultured in a tissue culture dish using a cell proliferation medium containing 10% bovine fetal serum added to MEM medium (manufactured by Nakaraitesk Co., Ltd.). The cell growth medium was removed from the monolayer culture dish and inoculated with feline calicivirus F-9 ATCC VR-782. Next, a cell maintenance medium containing 2% fetal bovine serum was added to the MEM medium, and the cells were cultured in a carbon dioxide incubator (CO 2 concentration 5%) at 37 ± 1 ° C. for 1 to 5 days. Feline calicivirus is a type of non-enveloped virus and is widely used as a substitute virus for norovirus that cannot be cultured in cells.
　培養後、倒立位相差顕微鏡を用いて細胞の形態を観察し、細胞に形態変化（細胞変性効果）が起こっていることを確認した。次に、培養液を１０００ｒｐｍ／分で３分間遠心分離し、得られた上澄み液を限外ろ過して試験ウイルス液とした。 After culturing, the morphology of the cells was observed using an inverted phase-contrast microscope, and it was confirmed that morphological changes (cytopathic effect) had occurred in the cells. Next, the culture solution was centrifuged at 1000 rpm / min for 3 minutes, and the obtained supernatant was ultrafiltered to obtain a test virus solution.
　実施例１で調製した本発明１～１０、比較例１～６の試験液０．９ｍＬに、試験ウイルス液０．１ｍＬを添加混合し、作用液とした。１分後に作用液をＭＥＭ培地で１００倍希釈し、１０倍希釈系列を作製した。なお、リン酸緩衝生理食塩水に試験ウイルス液を添加したものを対照として同様の操作を行った。 0.1 mL of the test virus solution was added and mixed with 0.9 mL of the test solutions of the present inventions 1 to 10 and Comparative Examples 1 to 6 prepared in Example 1 to prepare an action solution. After 1 minute, the working solution was diluted 100-fold with MEM medium to prepare a 10-fold dilution series. The same operation was performed using a phosphate buffered saline solution to which the test virus solution was added as a control.
（ウイルス感染価の測定）
　細胞増殖培地を用い、使用細胞を組織培養用マイクロプレート（９６穴）内で単層培養した後、細胞増殖培地を除去して細胞維持培地を０．１ｍＬずつ加えた。次に、作用液の１０倍希釈系列０．１ｍＬをそれぞれ４穴ずつに接種し、３７±１℃の炭酸ガスインキュベーター（ＣＯ２濃度５％）内で４～７日間培養した。培養後、倒立位相差顕微鏡を用いて細胞の形態変化（細胞変性効果）の有無を観察し、Ｒｅｅｄ－Ｍｕｅｎｃｈ法により５０％細胞培養感染量（ＴＣＩＤ５０）を算出して作用液１ｍＬ当たりの感染価に換算し、対照とした精製水の感染価と比較して、感染価対数減少値を算出した。 (Measurement of viral load)
Using the cell growth medium, the cells used were monolayer-cultured in a microplate for tissue culture (96 holes), the cell growth medium was removed, and 0.1 mL of the cell maintenance medium was added. Next, 0.1 mL of a 10-fold diluted series of the working solution was inoculated into 4 holes each, and cultured in a carbon dioxide incubator (CO 2 concentration 5%) at 37 ± 1 ° C. for 4 to 7 days. After culturing, observe the presence or absence of cell morphological changes (cytopathic effect) using an inverted phase difference microscope, calculate the 50% cell culture infection amount (TCID 50 ) by the Reed-Muench method, and infect per 1 mL of the working solution. The value was converted into a value and compared with the infectious value of purified water as a control, and the infectious value logarithmic reduction value was calculated.
　ウイルス除去効果の評価基準は、感染価対数減少値が１未満の場合を×、１以上１．５未満の場合を△、１．５以上２未満の場合を○、２以上の場合を◎とした。ウイルス感染価の評価結果を試験液の配合、感染価対数減少値と併せて表１、表２に示す。 The evaluation criteria for virus removal effect are x when the infectious value logarithm reduction value is less than 1, △ when it is 1 or more and less than 1.5, ○ when it is 1.5 or more and less than 2, and ◎ when it is 2 or more. did. The evaluation results of the virus infectious titer are shown in Tables 1 and 2 together with the formulation of the test solution and the decrease in the logarithm of the infectious titer.
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002
　表１に示すように、（ａ）０．０１質量％～５．０質量％のカチオン系ウイルス不活性化成分である１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイド、塩化ベンザルコニウム、塩化ベンゼトニウム、塩化ジデシルジメチルアンモニウム、及びクロルヘキシジングルコン酸塩のいずれかと、（ｂ）０．０２質量％～１０．０質量％のフマル酸、リン酸、乳酸のいずれかとを配合した本発明１～１０では、ネコカリシウイルス（Feline　calicivirus）に対して感染価対数減少値が１．５以上となり、ウイルス不活性化効果を有することが確認された。 As shown in Table 1, (a) 1,4-bis (3,3'-(1-decylpyridinium) methyloxy, which is a cationic virus inactivating component of 0.01% by mass to 5.0% by mass). ) Butangibromide, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, and chlorhexyzingurconate, and (b) 0.02% to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid. In the present inventions 1 to 10 in which any of the above was blended, it was confirmed that the feline calicivirus had an infectious titer logarithmic reduction value of 1.5 or more and had a virus inactivating effect.
　特に、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイドの配合量を０．１０質量％、フマル酸の配合量を０．２質量％とした本発明３、及び１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイドの配合量を０．１０質量％、リン酸の配合量を０．２質量％とした本発明５では、感染価対数減少値が３より大きくなり、より一層優れたウイルス不活性化効果が得られることが確認された。 In particular, the present invention has a compounding amount of 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butanjibromide of 0.10% by mass and a compounding amount of fumaric acid of 0.2% by mass. 3. And 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butanji bromide was blended in 0.10% by mass and phosphoric acid was blended in 0.2% by mass. In Invention 5, it was confirmed that the infectious titer logarithmic reduction value was larger than 3, and a further excellent virus inactivating effect could be obtained.
　これに対し、表２に示すように、（ａ）成分のみを配合した比較例５、６や、（ｂ）成分のみを配合した比較例１～３では、ネコカリシウイルス（Feline　calicivirus）に対して感染価対数減少値が１．５より小さくなり、十分なウイルス不活性化効果が認められなかった。また、（ａ）成分をカチオン系ウイルス不活性化成分に代えて、他のウイルス不活性化成分であるイソプロピルメチルフェノールを用いた比較例４では、（ｂ）成分を併用しても速効的なウイルス不活性化効果が得られず、（ｂ）成分に増強効果が認められなかった。 On the other hand, as shown in Table 2, Comparative Examples 5 and 6 containing only the component (a) and Comparative Examples 1 to 3 containing only the component (b) were against feline calicivirus. Therefore, the reduction value of the infectious titer log was smaller than 1.5, and a sufficient virus inactivating effect was not observed. Further, in Comparative Example 4 in which the component (a) was replaced with the cationic virus inactivating component and isopropylmethylphenol, which is another virus inactivating component, was used, the component (b) was used in combination for immediate effect. No virus inactivating effect was obtained, and no enhancing effect was observed in the component (b).
［ウイルス不活性化効果の確認試験２（Feline　calicivirus）］
（試験ウイルス液の調製）
　ＭＥＭ培地（ナカライテスク株式会社製）に牛胎仔血清を１０％加えた細胞増殖培地を用いてＣＲＦＫ細胞（ＪＲＢＣ細胞バンク）を組織培養シャーレ内に単層培養した。単層培養シャーレ内から細胞増殖培地を除去し、ネコカリシウイルス（Feline　calicivirus　F-9　ATCC　VR-782）を接種した。次に、ＭＥＭ培地に牛胎仔血清を２％加えた細胞維持培地を加えて３７±１℃の炭酸ガスインキュベーター（ＣＯ２濃度５％）内で１～５日間培養した。 [Confirmation test 2 of virus inactivating effect (Feline calicivirus)]
(Preparation of test virus solution)
CRFK cells (JRBC cell bank) were monolayer-cultured in a tissue culture dish using a cell proliferation medium containing 10% bovine fetal serum added to MEM medium (manufactured by Nakaraitesk Co., Ltd.). The cell growth medium was removed from the monolayer culture dish and inoculated with feline calicivirus F-9 ATCC VR-782. Next, a cell maintenance medium containing 2% fetal bovine serum was added to the MEM medium, and the cells were cultured in a carbon dioxide incubator (CO 2 concentration 5%) at 37 ± 1 ° C. for 1 to 5 days.
　培養後、倒立位相差顕微鏡を用いて細胞の形態を観察し、細胞に形態変化（細胞変性効果）が起こっていることを確認した。次に、培養液を１０００ｒｐｍ／分で３分間遠心分離し、得られた上澄み液を限外ろ過して試験ウイルス液とした。 After culturing, the morphology of the cells was observed using an inverted phase-contrast microscope, and it was confirmed that morphological changes (cytopathic effect) had occurred in the cells. Next, the culture solution was centrifuged at 1000 rpm / min for 3 minutes, and the obtained supernatant was ultrafiltered to obtain a test virus solution.
　実施例１で調製した本発明１１～２１、比較例７～１５の試験液０．９ｍＬに、試験ウイルス液０．１ｍＬを添加混合し、作用液とした。２０秒後に作用液をＭＥＭ培地で１００倍希釈し、１０倍希釈系列を作製した。なお、リン酸緩衝生理食塩水に試験ウイルス液を添加したものを対照として同様の操作を行った。 0.1 mL of the test virus solution was added and mixed with 0.9 mL of the test solution of the present inventions 11 to 21 and comparative examples 7 to 15 prepared in Example 1 to prepare an action solution. After 20 seconds, the working solution was diluted 100-fold with MEM medium to prepare a 10-fold dilution series. The same operation was performed using a phosphate buffered saline solution to which the test virus solution was added as a control.
　ウイルス感染価の測定方法、評価基準は実施例２と同様とした。ウイルス感染価の評価結果を試験液の配合、感染価対数減少値と併せて表３、表４に示す。 The method for measuring the viral infectivity titer and the evaluation criteria were the same as in Example 2. The evaluation results of the virus infectious titer are shown in Tables 3 and 4 together with the formulation of the test solution and the decrease in the logarithm of the infectious titer.
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000004
Figure JPOXMLDOC01-appb-T000004
　表３に示すように、（ａ）０．０１質量％～５．０質量％のカチオン系ウイルス不活性化成分である１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイド、塩化ベンザルコニウム、塩化ベンゼトニウム、塩化ジデシルジメチルアンモニウム、及びクロルヘキシジングルコン酸塩のいずれかと、（ｂ）０．０２質量％～１０．０質量％のフマル酸、リン酸、乳酸、クエン酸一水和物のいずれかとを配合した本発明１１～２１では、ネコカリシウイルス（Feline　calicivirus）に対して感染価対数減少値が２．５以上となり、処理後２０秒経過後においても十分なウイルス不活性化効果を示し、速効的なウイルス不活性化効果に優れることが確認された。 As shown in Table 3, (a) 1,4-bis (3,3'-(1-decylpyridinium) methyloxy, which is a cationic virus inactivating component of 0.01% by mass to 5.0% by mass). ) Butangibromide, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, and chlorhexyzingurconate, and (b) 0.02% to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid. In the present inventions 11 to 21 in which any of the citrate monohydrate was blended, the infectious titer log reduction value for Feline calicivirus was 2.5 or more, and even 20 seconds after the treatment. It was confirmed that it showed a sufficient virus inactivating effect and was excellent in a rapid virus inactivating effect.
　特に、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイドの配合量を０．１０質量％、フマル酸の配合量をそれぞれ０．０４質量％、０．２０質量％とした本発明１１、及び本発明１２、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイドの配合量を０．１０質量％、リン酸の配合量をそれぞれ０．０２質量％、０．０３質量％、０．２０質量％とした本発明１３、本発明１４、及び本発明１５、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイドの配合量を０．１０質量％、クエン酸一水和物の配合量を０．２０質量％とした本発明１７では、感染価対数減少値が３．０よりも大きくなり、より一層速効的なウイルス不活性化効果が得られることが確認された。 In particular, the blending amount of 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butanjibromide was 0.10% by mass, and the blending amount of fumaric acid was 0.04% by mass and 0. The blending amount of the present invention 11 and the present invention 12, 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butangibromide in an amount of 20% by mass was 0.10% by mass of phosphoric acid. The present invention 13, the present invention 14, and the present invention 15, 1,4-bis (3,3'-(1-), respectively, in which the blending amounts were 0.02% by mass, 0.03% by mass, and 0.20% by mass, respectively. In the present invention 17 in which the blending amount of decylpyridinium) methyloxy) butanedibromide was 0.10% by mass and the blending amount of citrate monohydrate was 0.20% by mass, the infectious titer logarithmic reduction value was 3.0. It was confirmed that a faster-acting virus inactivating effect could be obtained.
　これに対し、表４に示すように、（ａ）成分のみを配合した比較例１１～１４や、（ｂ）成分のみを配合した比較例７～９では、ネコカリシウイルス（Feline　calicivirus）に対して感染価対数減少値が１．５より小さくなり、速効的なウイルス不活性化効果が十分には認められなかった。また、（ａ）成分をカチオン系ウイルス不活性化成分に代えて、他のウイルス不活性化成分であるイソプロピルメチルフェノールを用いた比較例１０では、（ｂ）成分を併用しても速効的なウイルス不活性化効果が得られず、（ｂ）成分に増強効果が認められなかった。 On the other hand, as shown in Table 4, Comparative Examples 11 to 14 containing only the component (a) and Comparative Examples 7 to 9 containing only the component (b) were against feline calicivirus. Therefore, the reduction value of the infectious titer log was smaller than 1.5, and the rapid virus inactivating effect was not sufficiently observed. Further, in Comparative Example 10 in which the component (a) was replaced with the cationic virus inactivating component and isopropylmethylphenol, which is another virus inactivating component, was used, even if the component (b) was used in combination, the effect was rapid. No virus inactivating effect was obtained, and no enhancing effect was observed in the component (b).
［ウイルス不活性化効果の確認試験３（Feline　enteric　coronavirus）］
（試験ウイルス液の調製）
　ネココロナウイルス（Feline　enteric　coronavirus）をネコ胎児由来細胞（fcwf-4：feline　catus　whole　fetus）に感染させ、細胞培養面積の約９０％以上が細胞変性効果を示したとき、－８０℃の冷蔵庫に保存した。その後、凍結融解操作を行い、３５００ｒｐｍで１０分間遠心した上清を用いて限外濾過膜で濃縮したウイルス液を供試ウイルスとした。 [Confirmation test 3 of virus inactivating effect (Feline enteric coronavirus)]
(Preparation of test virus solution)
When feline enteric coronavirus is infected with feline feline-derived cells (fcwf-4: feline catus whole fetus) and more than 90% of the cell culture area shows cytopathic effect, it is placed in a refrigerator at -80 ° C. saved. Then, a freeze-thaw operation was performed, and a virus solution concentrated with an ultrafiltration membrane using a supernatant centrifuged at 3500 rpm for 10 minutes was used as a test virus.
　実施例１で調製した本発明１２の試験液０．９ｍＬに、試験ウイルス液０．１ｍＬを添加混合し、作用液とした。３分後に作用液をＭＥＭ培地で１００倍希釈し作用停止させたものを感染価測定用試料の原液としてウイルス感染価を測定した。なお、リン酸緩衝生理食塩水に試験ウイルス液を添加したものを対照として同様の操作を行った。 0.1 mL of the test virus solution was added and mixed with 0.9 mL of the test solution of the present invention 12 prepared in Example 1 to prepare an action solution. After 3 minutes, the working solution was diluted 100-fold with MEM medium to stop the action, and the virus infectious titer was measured as the stock solution of the sample for infectious titer measurement. The same operation was performed using a phosphate buffered saline solution to which the test virus solution was added as a control.
　試験の結果、本発明１２のウイルス不活性化剤組成物を作用させた感染価測定用試料では、３分後にネココロナウイルス（Feline　enteric　coronavirus）が検出限界値未満となり、本発明１２のウイルス不活性化剤組成物はネココロナウイルス（Feline　enteric　coronavirus）に対するウイルス不活性化効果を示すことが分かった。 As a result of the test, in the sample for measuring the infectious titer on which the virus inactivating agent composition of the present invention 12 was allowed to act, the feline enteric coronavirus became less than the detection limit value after 3 minutes, and the virus of the present invention 12 was not virus-free. It was found that the activator composition exhibits a virus inactivating effect on cat coronavirus (Feline enteric coronavirus).
　本発明は、ウイルス不活性化における速効性が優れるウイルス不活性化剤組成物およびウイルス不活性化効力増強方法、並びにウイルス不活性化方法であり、特にウイルスで汚染された場所等に直接スプレー等により塗布されるウイルス不活性化剤組成物として好適に用いられる。 The present invention is a virus inactivating agent composition having an excellent rapid effect on virus inactivation, a method for enhancing the efficacy of the virus inactivating, and a method for inactivating the virus, and in particular, direct spraying or the like on a place contaminated with a virus or the like. It is suitably used as a virus inactivating agent composition applied by.

Claims (8)

  1. 　（ａ）ウイルス不活性化成分として、０．０１質量％～５．０質量％のカチオン系ウイルス不活性化成分と、（ｂ）ウイルス不活性化効力増強成分として、０．０２質量％～１０．０質量％のフマル酸、リン酸、乳酸、及びクエン酸からなる群より選択される１種又は２種以上と、水と、を配合したことを特徴とするウイルス不活性化剤組成物。 (A) 0.01% by mass to 5.0% by mass of a cationic virus inactivating component as a virus inactivating component, and (b) 0.02% by mass to 10% as a virus inactivating efficacy enhancing component. A virus inactivating agent composition comprising one or more selected from the group consisting of 0.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid, and water.
  2. 　前記カチオン系ウイルス不活性化成分が、ジアルキルジメチルアンモニウム塩（但し、前記アルキル基は同一又は相異なり、炭素数８～２０の直鎖飽和炭化水素を表す。）、トリアルキル（３－トリエトキシシリルプロピル）アンモニウム塩（但し、前記アルキル基は同一又は相異なり、炭素数１～１８の直鎖飽和炭化水素を表す。）、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタン塩、ベンザルコニウム塩、ベンゼトニウム塩、クロルヘキシジン塩からなる群より選択される１種又は２種以上であることを特徴とする請求項１に記載のウイルス不活性化剤組成物。 The cationic virus inactivating component is a dialkyldimethylammonium salt (however, the alkyl group is the same or different and represents a linear saturated hydrocarbon having 8 to 20 carbon atoms), trialkyl (3-triethoxysilyl). Propyl) ammonium salt (however, the alkyl group is the same or different and represents a linear saturated hydrocarbon having 1 to 18 carbon atoms), 1,4-bis (3,3'-(1-decylpyridinium) methyl. Oxy) The virus inactivating agent composition according to claim 1, wherein the composition is one or more selected from the group consisting of a butane salt, a benzalkonium salt, a benzethonium salt, and a chlorhexidine salt.
  3. 　前記カチオン系ウイルス不活性化成分が、１，４－ビス（３，３’　－（１－デシルピリジニウム）メチルオキシ）ブタンジブロマイド、塩化ベンザルコニウム、塩化ベンゼトニウム、塩化ジデシルジメチルアンモニウム、クロルヘキシジングルコン酸塩、及び塩化オクタデシルジメチル（３－トリエトキシシリルプロピル）アンモニウムからなる群より選択される１種又は２種以上であることを特徴とする請求項２に記載のウイルス不活性化剤組成物。 The cationic virus inactivating component is 1,4-bis (3,3'-(1-decylpyridinium) methyloxy) butane dibromide, benzalkonium chloride, benzethonium chloride, didecyldimethylammonium chloride, chlorhexidine glucon. The virus inactivating agent composition according to claim 2, wherein the composition is one or more selected from the group consisting of the acid salt and octadecyldimethyl (3-triethoxysilylpropyl) ammonium chloride.
  4. 　さらに、（ｃ）エタノールを１０質量％～８０質量％を配合したことを特徴とする請求項１～３のいずれか１項に記載のウイルス不活性化剤組成物。 The virus inactivating agent composition according to any one of claims 1 to 3, further comprising (c) 10% by mass to 80% by mass of ethanol.
  5. 　前記（ｃ）エタノールの配合量が、３５質量％～６５質量％であることを特徴とする請求項４に記載のウイルス不活性化剤組成物。 The virus inactivating agent composition according to claim 4, wherein the blending amount of (c) ethanol is 35% by mass to 65% by mass.
  6. 　前記（ａ）ウイルス不活性化成分に対する前記（ｂ）ウイルス不活性化効力増強成分の配合質量比（ａ）／（ｂ）が、０．００１≦（ａ）／（ｂ）≦２５０であることを特徴とする請求項１～５のいずれか１項に記載のウイルス不活性化剤組成物。 The compounding mass ratio (a) / (b) of the (b) virus inactivating efficacy enhancing component to the (a) virus inactivating component is 0.001 ≦ (a) / (b) ≦ 250. The virus inactivating agent composition according to any one of claims 1 to 5.
  7. 　（ａ）ウイルス不活性化成分として、０．０１質量％～５．０質量％のカチオン系ウイルス不活性化成分と、水と、を含有するウイルス不活性化剤組成物に、（ｂ）ウイルス不活性化効力増強成分として、０．０２質量％～１０．０質量％のフマル酸、リン酸、乳酸、及びクエン酸からなる群より選択される１種又は２種以上を添加することを特徴とするウイルス不活性化効力増強方法。 (A) A virus inactivating agent composition containing 0.01% by mass to 5.0% by mass of a cationic virus inactivating component and water as a virus inactivating component, and (b) a virus. It is characterized by adding one or more selected from the group consisting of 0.02% by mass to 10.0% by mass of fumaric acid, phosphoric acid, lactic acid, and citric acid as an inactivating efficacy enhancing component. A method for enhancing the efficacy of virus inactivation.
  8. 　請求項１～６のいずれか１項に記載のウイルス不活性化剤組成物をノンエンベロープウイルスに対して接触させるノンエンベロープウイルスの不活性化方法。 A method for inactivating a non-enveloped virus in which the virus inactivating agent composition according to any one of claims 1 to 6 is brought into contact with the non-enveloped virus.
PCT/JP2021/027348 2020-08-20 2021-07-21 Virus inactivating agent composition, virus inactivation efficacy enhancing method, and virus inactivation method WO2022038955A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202180058669.4A CN116056570A (en) 2020-08-20 2021-07-21 Virus inactivating agent composition, method for enhancing virus inactivating efficacy, and method for inactivating virus
JP2022543335A JPWO2022038955A1 (en) 2020-08-20 2021-07-21

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-139320 2020-08-20
JP2020139320 2020-08-20

Publications (1)

Publication Number Publication Date
WO2022038955A1 true WO2022038955A1 (en) 2022-02-24

Family

ID=80350349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/027348 WO2022038955A1 (en) 2020-08-20 2021-07-21 Virus inactivating agent composition, virus inactivation efficacy enhancing method, and virus inactivation method

Country Status (3)

Country Link
JP (1) JPWO2022038955A1 (en)
CN (1) CN116056570A (en)
WO (1) WO2022038955A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115839522A (en) * 2022-11-01 2023-03-24 光谷洁净(武汉)科技有限公司 High-efficient low resistance air cleaner

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009526060A (en) * 2006-02-09 2009-07-16 ゴジョ・インダストリーズ・インコーポレイテッド Antiviral method
US20090232748A1 (en) * 2003-11-07 2009-09-17 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
JP2010195782A (en) * 2002-05-29 2010-09-09 L'air Liquide Sante Internatl Disinfectant with activity against hepatitis b virus
CN106577756A (en) * 2016-11-28 2017-04-26 青岛源之林农业科技开发有限公司 Influenza virus disinfectant
JP2017528463A (en) * 2014-09-09 2017-09-28 ロンザ インコーポレーテッド Disinfecting composition containing a quaternary ammonium compound
JP2018090564A (en) * 2016-11-30 2018-06-14 株式会社Adeka Cleaning sheet
JP2019532024A (en) * 2016-08-11 2019-11-07 エコラボ ユーエスエー インコーポレイティド Interactions between antimicrobial quaternary compounds and anionic surfactants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101319151B1 (en) * 2006-02-09 2013-10-17 고조 인더스트리즈, 인크 Antiviral disinfectants and applications
US8119115B2 (en) * 2006-02-09 2012-02-21 Gojo Industries, Inc. Antiviral method
US9278107B2 (en) * 2008-12-25 2016-03-08 Hiroshima University Antibacterial agent composition and antiviral agent composition comprising silicon-containing compound; antibacterializing method, cleaning/mouth rinsing method; method for fixing antibacterial agent and antiviral agent
BR112013018933A2 (en) * 2011-02-10 2016-09-13 Unilever Nv antiviral, liquid antiseptic, and personal cleansing compositions for solid and liquid hard surface cleaning, antimicrobial, hand sanitizer, surface disinfection method and use of a composition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010195782A (en) * 2002-05-29 2010-09-09 L'air Liquide Sante Internatl Disinfectant with activity against hepatitis b virus
US20090232748A1 (en) * 2003-11-07 2009-09-17 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
JP2009526060A (en) * 2006-02-09 2009-07-16 ゴジョ・インダストリーズ・インコーポレイテッド Antiviral method
JP2017528463A (en) * 2014-09-09 2017-09-28 ロンザ インコーポレーテッド Disinfecting composition containing a quaternary ammonium compound
JP2019532024A (en) * 2016-08-11 2019-11-07 エコラボ ユーエスエー インコーポレイティド Interactions between antimicrobial quaternary compounds and anionic surfactants
CN106577756A (en) * 2016-11-28 2017-04-26 青岛源之林农业科技开发有限公司 Influenza virus disinfectant
JP2018090564A (en) * 2016-11-30 2018-06-14 株式会社Adeka Cleaning sheet

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115839522A (en) * 2022-11-01 2023-03-24 光谷洁净(武汉)科技有限公司 High-efficient low resistance air cleaner
CN115839522B (en) * 2022-11-01 2023-08-25 光谷洁净(武汉)科技有限公司 High-efficient low resistance air cleaner

Also Published As

Publication number Publication date
JPWO2022038955A1 (en) 2022-02-24
CN116056570A (en) 2023-05-02

Similar Documents

Publication Publication Date Title
JP5925758B2 (en) Antibacterial composition
JP5554926B2 (en) Antiviral method
JP5788385B2 (en) Antibacterial composition
EP2672828B1 (en) Antimicrobial composition
CA2666146A1 (en) Methods of inactivating viruses
JP2013506650A (en) Sanitizing composition
JP6704099B1 (en) Sterilizing or virus inactivating agent composition, and method for enhancing efficacy of sterilizing or virus inactivating agent
WO2022038955A1 (en) Virus inactivating agent composition, virus inactivation efficacy enhancing method, and virus inactivation method
JP2017105723A (en) Composition having calicivirus inactivation effect
WO2022038630A1 (en) Surface cleaning composition and use thereof
CN113473858A (en) Bactericidal or viral inactivating agent composition and method for enhancing bactericidal or viral inactivating efficacy
JP2022125090A (en) Virus deactivation composition
WO2021095636A1 (en) Virus inactivation agent composition and virus inactivation efficacy enhancement method, and virus inactivation method
TWI841480B (en) Virus inactivation agent composition and method for increasing virus inactivation efficiency, and virus inactivation method
JP2019531324A5 (en)
JP2010285387A (en) Norovirus deactivator
JP2016117693A (en) Water-soluble composition having antibacterial and antivirus property
JP7376903B2 (en) Virus inactivators and sanitary materials
JP2018197205A (en) Virus deactivator, norovirus deactivator and sanitary material
JP2024083006A (en) Leave-on liquid fungicide composition
JP2011073982A (en) Compounded composition
JP2024089698A (en) Leave-on disinfectant compositions
JP2023017494A (en) Method for protecting skin from bacteria or virus
JP2023017691A (en) Packed liquid composition
JP2022056421A (en) Antiviral agent, disinfectant, and detergent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21858104

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022543335

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21858104

Country of ref document: EP

Kind code of ref document: A1